Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age

Jeremy N Friedman, Michael J Rieder, Jennifer M Walton; Canadian Paediatric Society
Acute Care Committee, Drug Therapy and Hazardous Substances Committee
Paediatr Child Health 2014;19(9):485-91
Posted: Nov 3 2014

Abstract
Bronchiolitis is the most common reason for admission to hospital in the first year of life. There is tremendous variation in the clinical management of this condition across Canada and around the world, including significant use of unnecessary tests and ineffective therapies. This statement pertains to generally healthy children ≤2 years of age with bronchiolitis. The diagnosis of bronchiolitis is based primarily on the history of illness and physical examination findings. Laboratory investigations are generally unhelpful. Bronchiolitis is a self-limiting disease, usually managed with supportive care at home. Groups at high risk for severe disease are described and guidelines for admission to hospital are presented. Evidence for the efficacy of various therapies is discussed and recommendations are made for management. Monitoring requirements and discharge readiness from hospital are also discussed.

Key Words: Respiratory distress; RSV; URTI; Wheezing

Bronchiolitis affects more than one-third of children in the first two years of life and is the most common cause for admission to hospital in their first year. Over the past 30 years, hospitalization rates have increased from 1% to 3% of all infants.\[1\] Rising admissions have been costly for the health care system,\[9\] and reflect significant morbidity\[10\] and impact on families.

Despite the existence of numerous clinical practice guidelines, including the often-quoted American Academy of Pediatrics (AAP) clinical practice guideline published in 2006,\[11\] there is tremendous variation\[11\] in approaches to diagnosis, monitoring and management. Initiatives to standardize care for bronchiolitis\[12\] have demonstrated decreased use of diagnostic testing and resource utilization, along with cost reduction and improved outcomes.\[7\][13] However, while there has been some decrease in testing and treatments since the release of the AAP recommendations,\[14\] uptake has not been widespread.

The goals of this statement are to build on the comprehensive peer-reviewed AAP statement\[1\] by incorporating new evidence published over the past eight years, while providing the clinician with recommendations to help guide diagnosis, monitoring and management of previously healthy children one to 24 months of age who present with signs of bronchiolitis (Figure 1). These recommendations are intended to support a decrease in the use of unnecessary diagnostic studies and ineffective medications and interventions. This statement does not apply to children with chronic lung disease, immunodeficiency or other serious underlying chronic disease. The prevention of and potential long-term effects from bronchiolitis are beyond the scope of this statement but are well described in the literature and other statements from the Canadian Paediatric Society.\[4][6]

Diagnosis
Bronchiolitis is a clinical diagnosis based on a directed history and physical examination. Bronchiolitis may present with a
wide range of symptoms and severity, from a mild upper respiratory tract infection (URTII) to impending respiratory failure (Table 1). Bronchiolitis typically presents with a first episode of wheezing before the age of 12 months. The course begins with a two-to-three-day viral prodrome of fever, cough and rhinorrhea progressing to tachypnea, wheeze, crackles and a variable degree of respiratory distress. Signs of respiratory distress may include grunting, nasal flaring, indrawing, retractions or abdominal breathing. There may or may not be a history of exposure to an individual with a viral URTII.

### TABLE 1

**History, symptoms and signs of viral bronchiolitis**

<table>
<thead>
<tr>
<th>Preceding viral upper respiratory tract infection, cough and/or rhinorrhea</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure to an individual with viral upper respiratory tract infection</td>
</tr>
<tr>
<td>Signs of respiratory illness may also include:</td>
</tr>
<tr>
<td>• Tachypnea</td>
</tr>
<tr>
<td>• Intercostal and/or substernal retractions</td>
</tr>
<tr>
<td>• Accessory muscle use</td>
</tr>
<tr>
<td>• Nasal flaring</td>
</tr>
<tr>
<td>• Grunting</td>
</tr>
<tr>
<td>• Colour change or apnea</td>
</tr>
<tr>
<td>• Wheezing or crackles</td>
</tr>
<tr>
<td>• Lower O₂ saturations</td>
</tr>
</tbody>
</table>

While the majority of wheezing infants who present acutely between November and April most likely have viral bronchiolitis, clinicians should consider a broad differential diagnosis, especially in patients with atypical presentations such as severe respiratory distress, no viral URTII symptoms and/or frequent recurrences (Table 2).[7]

### Investigations

Diagnostic studies are not indicated for most children with bronchiolitis (Table 3). Tests are often unhelpful and can lead to unnecessary admissions, further testing and ineffective therapies. Evidence-based reviews have not supported the use of diagnostic testing in typical cases of bronchiolitis.[17]

**Chest radiograph (CXR)** of infants with bronchiolitis often reveals nonspecific, patchy hyperinflation and areas of atelectasis,[8] which may be misinterpreted as consolidation. This can lead to increased and inappropriate use of antibiotics.[15] In infants with typical bronchiolitis, a recent prospective study found CXR findings inconsistent with bronchiolitis in only two of 265 infants, and in no case did the results change acute management.[16] While routine CXR is not supported by current evidence, it should be considered when the diagnosis of bronchiolitis is unclear, the rate of improvement is not as expected or the severity of disease raises other diagnostic possibilities such as bacterial pneumonia.

**Nasopharyngeal swabs** for respiratory viruses generally are not helpful from a diagnostic perspective and do not alter management in most cases. They are not routinely recommended unless required for infection control (ie, the cohorting of hospitalized patients). Recently, however, the high rate of coinfection with multiple viruses has called even this indication into question.[17]

**Complete blood count** has not been found to be useful in predicting serious bacterial infections (SBI).[18]

**Bacterial cultures:** The incidence of concomitant SBI is believed to be very low, but not insignificant, in febrile infants with bronchiolitis.[7][19][21] Infants in their first two months of life have the greatest risk of SBI, especially urinary tract infection.[19][22] Rates vary from 0% to 6.1%. Bacteremia is rare (<1%) in most studies. Meningitis complicating bronchiolitis is also extremely rare. A study in the office setting of febrile infants with bronchiolitis found no cases of SBI out of 125 patients with bronchiolitis, compared with 212 of 1933 (11%) in a febrile group of similar age without bronchiolitis.[19]

**TABLE 2**

**Differential diagnosis for wheezing in young children**

<table>
<thead>
<tr>
<th>Viral bronchiolitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
</tr>
<tr>
<td>Other pulmonary infections (eg, pneumonia)</td>
</tr>
<tr>
<td>Laryngotracheomalacia</td>
</tr>
<tr>
<td>Foreign body aspiration</td>
</tr>
<tr>
<td>Gastroesophageal reflux</td>
</tr>
<tr>
<td>Congestive heart failure</td>
</tr>
<tr>
<td>Vascular ring</td>
</tr>
<tr>
<td>Allergic reaction</td>
</tr>
<tr>
<td>Cystic fibrosis</td>
</tr>
<tr>
<td>Mediastinal mass</td>
</tr>
<tr>
<td>Tracheoesophageal fistula</td>
</tr>
</tbody>
</table>

*Adapted from reference 7*

Physical examination findings of importance include increased respiratory rate, signs of respiratory distress, and crackles and wheezing on auscultation. Measurement of oxygen saturation often shows decreased saturation levels. Signs of dehydration may be present if respiratory distress has been sufficient to interfere with feeding.
**Role of diagnostic studies in typical cases of bronchiolitis**

<table>
<thead>
<tr>
<th>Type</th>
<th>Specific indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest radiograph</td>
<td>Only if severely or course suggests alternate diagnosis (Table 2)</td>
</tr>
<tr>
<td>Nasopharyngeal swabs</td>
<td>Only if required for cohorting admitted patients</td>
</tr>
<tr>
<td>Complete blood count</td>
<td>Generally not helpful in diagnosis or monitoring of routine cases</td>
</tr>
<tr>
<td>Blood gas</td>
<td>Only if concerned about potential respiratory failure</td>
</tr>
<tr>
<td>Bacterial cultures</td>
<td>Not recommended routinely; may be required based on clinical findings and a child’s age</td>
</tr>
</tbody>
</table>

**Decision to admit**

The decision to admit should be based on clinical judgment and consider the infant’s respiratory status, ability to maintain adequate hydration, risk for progression to severe disease and the family’s ability to cope (Tables 4 and 5). Physicians should keep in mind that the disease tends to worsen over the first 72 h when deciding whether to hospitalize. Clini- cal scores and individual findings on physical examination cannot be relied on in isolation to predict outcomes. Severity scoring systems exist; however, none are widely used and few have demonstrated predictive validity. Respiratory rate, subcostal retractions and oxygen need may be the most helpful parameters used in the various bronchiolitis severity scores.

Repeated observations over a period of time are important because there may be significant temporal variability. Consistent predictors of hospitalization in outpatient populations include age (<3 months) and history of prematurity (<35 weeks’ gestation). Another study found that patients with any three of the following four factors – decreased hydration, accessory muscle score >6 of 9, O₂ saturation <92% and respiratory rate >60 breaths/min – had a 13-fold increase in hospitalization rate.

The role of pulse oximetry in clinical decision-making remains controversial. While oxygen saturations of <94% are associated with a more than five-fold increase in likelihood of admission, it is important to recognize that setting arbitrary thresholds for oxygen therapy will influence admission rates. This effect was illustrated in a survey of emergency department physicians that showed a significant increase in the likelihood of recommending admission by simply reducing saturation from 94% to 92% in clinical vignettes.

**Management**

Bronchiolitis is a self-limiting disease. Most children have mild disease and can be managed with supportive care at home. For those requiring admission, supportive care with assisted feeding, minimal handling, gentle nasal suctioning and oxygen therapy still forms the mainstay of treatment (Table 6).

**Groups at higher risk for severe disease**
- Infants born pretermly (<35 weeks’ gestation)
- <3 months of age at presentation
- Hemodynamically significant cardiopulmonary disease
- Immunodeficiency

**Guidelines for admission may include**
- Signs of severe respiratory distress (eg, indrawing, grunting, RR >70/min)
- Supplemental O₂ required to keep saturations >90%
- Dehydration or history of poor fluid intake
- Cyanosis or history of apnea
- Infant at high risk for severe disease (Table 4)
- Family unable to cope

**Treating bronchiolitis**

<table>
<thead>
<tr>
<th>Recommended</th>
<th>Evidence equivocal</th>
<th>Not recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxygen</td>
<td>Epinephrine nebulizaton</td>
<td>Salbutamol (Ventolin; GlaxoSmithKline, USA)</td>
</tr>
<tr>
<td></td>
<td>Nasal suctioning</td>
<td>Corticosteroids</td>
</tr>
<tr>
<td></td>
<td>3% hypertonic saline nebulization</td>
<td>Antibiotics</td>
</tr>
<tr>
<td></td>
<td>Combined epinephrine and dexamethasone</td>
<td>Antivirals</td>
</tr>
<tr>
<td></td>
<td>Cool mist therapies or therapy with saline aerosol</td>
<td></td>
</tr>
</tbody>
</table>

**Discharge from hospital**

- Tachypnea and work of breathing improved
- Maintain O₂ saturations >90% without supplemental oxygen OR stable for home oxygen therapy
- Adequate oral feeding
- Education provided and appropriate follow-up arranged
Therapies recommended based on evidence

Oxygen
Supplemental oxygen therapy is a mainstay of treatment in hospital. Oxygen should be administered if saturations fall below 90% and used to maintain saturations at ≥90%.[1] To minimize handling, oxygen is usually administered via nasal cannulae, face mask or a head box. A recent alternative is humidified high-flow nasal cannula therapy,[28] which may be better tolerated and potentially decrease the need for mechanical ventilation.[29][30] At this point, there is insufficient evidence to determine effectiveness.[31] There are, however, ongoing studies investigating this question, which will likely help to guide practice in the near future.

Hydration
Some degree of fluid supplementation is required in 30% of hospitalized patients with bronchiolitis.[32]

Frequent feeds should be encouraged and breastfeeding supported; both may be facilitated by providing supplemental oxygen. Infants with a respiratory rate >60 breaths/min, particularly those with nasal congestion, may have an increased risk of aspiration and may not be safe to feed orally.[1] When supplemental fluids are required, a recent randomized trial found nasogastric (NG) and intravenous (IV) routes to be equally effective, with no difference in length of hospital stay.[33] NG insertion may require fewer attempts and have a higher success rate than IV placement. If NG bolus feeds are not tolerated, slow continuous feeds are an option. If the IV route is used, isotonic fluids (0.9% NaCl/5% dextrose) are preferred for maintenance, with regular monitoring of serum Na[34] because of the risk of hyponatremia.[35]

Therapies for which evidence is equivocal

Epinephrine
Some studies have shown that epinephrine nebulization may be effective for reducing hospital admissions,[36] and one trial showed that combined treatment with epinephrine and steroids reduced admissions.[37] However, the evidence remains insufficient to support routine use of epinephrine in the emergency department. It may be reasonable to administer a dose of epinephrine and carefully monitor clinical response; however, unless there is clear evidence of improvement, continued use is not appropriate. A systematic review of 19 studies evaluating the use of epinephrine in bronchiolitis shows no effect on length of hospital stay[36] and there is insufficient evidence to support its routine use in admitted patients.

Nasal suctioning
As for many long-standing and commonly used therapies for children, there is scant evidence supporting the use of nasal suctioning in the management of bronchiolitis. While it appears that suctioning mucus out of blocked nares would be a harmless procedure, one recent study has suggested that deep suctioning and long intervals between suctioning are associated with increased length of stay.[38] This suggests that if suctioning is performed, it should be done superficially and reasonably frequently.

3% hypertonic saline nebulization
The value of nebulized 3% hypertonic saline is being strongly debated and definitive recommendations will likely require further accumulation of evidence. It is hypothesized that hypertonic saline increases mucociliary clearance and rehydrates airway surface liquid, and there is evidence of reduced clinical severity scores in both inpatient and outpatient populations with no reports of significant adverse events.[39] A Cochrane review of 11 trials found that nebulized hypertonic saline was associated with a reduced length of stay of one day in settings where the admission was longer than three days. The optimal treatment regimen remains unclear. The most commonly used regimen in most trials has been 3% saline with or without added bronchodilator by jet nebulizer three times daily, with an interval of 8 h between treatments. Further studies since the Cochrane review have shown mixed results.[40][41] Nebulized 3% saline may be helpful in the inpatient setting; this treatment appears primarily to benefit patients with a longer length of stay. Evidence does not currently support its routine use in the outpatient setting.

Combination epinephrine and dexamethasone
One publication from the Pediatric Emergency Research Canada group found an unexpected synergism between the administration of nebulized epinephrine with oral dexamethasone. The combination appeared to result in a reduced hospitalization rate, with a number needed to treat of 11. However, these results were rendered nonsignificant when adjusted for multiple comparisons.[37] More research is needed to assess the role of combination therapies. Pending better definition of its risks and benefits, this combination is not recommended for the therapy of otherwise healthy children with bronchiolitis.

Therapies not recommended based on evidence

Salbutamol (Ventolin; GlaxoSmithKline, USA)
Children with bronchiolitis present with a wheeze that is clinically similar to that observed with asthma. However, the pathophysiology of bronchiolitis is such that the airways are obstructed[42] rather than constricted. Furthermore, infants appear to have inadequate β-agonist lung receptor sites and immature bronchiolar smooth muscles.[43] While studies have shown small improvements in clinical scores, bronchodilators have not been shown to improve O2 saturation, do not reduce admission rates and do not shorten the duration of stay in hospital.[42] When the diagnosis of bronchiolitis is clear, a trial of salbutamol is not currently recommended.[1]
Corticosteroids
Corticosteroids, such as dexamethasone, prednisone or inhaled glucocorticoids, are not associated with a clinically significant improvement in disease, as measured by reduction in clinical scores, rates of hospitalization and length of hospital stay.\textsuperscript{[1]}[2][3][4][46] Furthermore, any small benefit that corticosteroids may offer must be weighed against the risks of steroid treatment. Corticosteroids are not recommended for routine use in bronchiolitis.

Antibiotics
Many children with acute bronchiolitis are prescribed an antibiotic. However, bacterial infection in otherwise healthy children with bronchiolitis is exceedingly rare.\textsuperscript{[46]} Research on the role of antibiotics in bronchiolitis is limited and has, to date, failed to identify any benefit. Further research is needed to develop criteria for identifying the minority of patients at high risk for secondary bacterial infection.\textsuperscript{[46]} Currently, antibiotics should not be used except in cases in which there is clear, documented evidence of a secondary bacterial infection.\textsuperscript{[1]}

Antivirals
Antiviral therapies, such as ribavirin, are expensive, cumbersome to administer, provide limited benefit and are potentially toxic to care providers and, thus, are not recommended for the routine treatment of bronchiolitis in otherwise healthy children.\textsuperscript{[1]} In patients with or at risk for particularly severe disease, antivirals could be considered, but this decision should be made on an individual basis in consultation with appropriate subspecialists.\textsuperscript{[1][4][7][48]}

Chest physiotherapy
Nine clinical trials comparing physiotherapy with no treatment were reviewed.\textsuperscript{[49]} Neither vibration and percussion nor passive expiratory techniques were shown to improve clinical scores or to reduce hospital stay or duration of symptoms. Chest physiotherapy is not recommended for the treatment of bronchiolitis.\textsuperscript{[1][4][9]}

Cool mist therapies or aerosol therapy with isotonic saline
Cool mist and other aerosol therapies have been used for some time to manage bronchiolitis, with scant evidence supporting their efficacy. A recent Cochrane review concluded that there is no evidence supporting or refuting the use of cool mist and other aerosols for managing bronchiolitis.\textsuperscript{[50]}

Other therapies used for critically ill patients with severe bronchiolitis, such as helium/oxygen, nasal continuous positive airway pressure, mechanical ventilatory support and surfactant, are beyond the scope of this statement.\textsuperscript{[51][53]}

Monitoring in hospital
Patients with bronchiolitis should be cared for in an environment with ready access to suction equipment and supplemental oxygen that can be delivered at measurable rates. Close attention must be devoted to infection control processes. Respiratory contact isolation may reduce nosocomial transmission, but there is conflicting evidence regarding the benefits of co-horting patients.\textsuperscript{[12][3][4][55]}

The most important component of monitoring infants admitted with bronchiolitis is regular and repeated clinical assessments by staff with appropriate expertise in the respiratory assessment of young children. Monitoring should include assessment and documentation of respiratory rate, work of breathing, oxygen saturation, findings on auscultation and general condition, including feeding and hydration status. Scoring tools have been developed in an attempt to standardize assessments and facilitate communication among caregivers. However, there is insufficient evidence of impact on patient outcomes to recommend using any specific tool.\textsuperscript{[56][58]}

The use of electronic monitoring of vital signs and oxygen saturation should not be considered to be a substitute for regular clinical assessments by experienced personnel. Furthermore, there is growing evidence to suggest that continuous monitoring may prolong length of stay, particularly if staff react to normal transient dips in oxygen saturation or changes in heart and respiratory rates with interventions such as restarting oxygen therapy.\textsuperscript{[59]} The accuracy of pulse oximetry is relatively poor, particularly at saturations <90%,\textsuperscript{[60]}

The primary rationale for cardiac and respiratory monitoring is to detect episodes of apnea requiring intervention. The incidence of apnea in RSV bronchiolitis may be lower than previously believed. In a large study involving 691 infants <6 months of age, only 2.7% had documented apnea, and all had risk criteria of either a previous apneic episode or young age (<1 month or <48 weeks postconception in premature infants).\textsuperscript{[61]} Continuous electronic cardiac and respiratory monitoring may be useful for high-risk patients in the acute phase of illness but are not necessary for the vast majority of patients with bronchiolitis.

Determining oxygen saturation can aid in decisions about escalating or weaning oxygen therapy. However, the issue of continuous versus intermittent monitoring of oxygen saturation is controversial. Continuous monitoring may be more sensitive for identifying patients who are deteriorating and need escalation of treatment. At the same time, many healthy infants exhibit transient \textsuperscript{[62][63]} and length of stay may be prolonged if oxygen therapy is based on arbitrary saturation targets. Several clinical trials currently underway are attempting to determine best practices in this area. Until clear evidence is available, a reasonable approach is to adjust the intensity of oxygen saturation monitoring according to the patient’s clinical status. Continuous saturation monitoring is appropriate for high-risk patients early in the course of disease, while intermittent monitoring is most appropriate for lower-risk patients and for all patients once they are feeding well, weaning from supplemental oxygen and showing improvement in work of breathing.
The American Academy of Pediatrics, Subcommittee on Diagnosis and Management of Bronchiolitis, Diagnosis and management of bronchiolitis. Pediatrics 2006;118(4):1774-93.


CPS ACUTE CARE COMMITTEE

Members: Laurel Chauvin-Kimoff MD (Chair), Isabelle Chevalier MD (Board Representative), Catherine A Farrell MD, Jeremy N Friedman MD, Angelo Mikrogianakis MD (past Chair), Oliva Ortiz-Alvarez MD.

 Liaisons: Dominic Allain MD, CPS Paediatric Emergency Medicine Section; Tracy MacDonald BScN, Canadian Association of Paediatric Health Centres; Jennifer M Walton MD, CPS Hospital Paediatrics Section

CPS DRUG THERAPY AND HAZARDOUS SUBSTANCES COMMITTEE

Members: Mark L Bernstein MD, Francois Boucher MD (Board Representative), Ran D Goldman MD, Geer’t Jong MD, Philippe Ovetchkine MD, Michael J Rieder MD (Chair),

 Liaisons: Daniel Louis Keene MD, Health Canada; Doreen Matsui MD (past Chair)

Principal authors: Jeremy N Friedman MD, Michael J Rieder MD, Jennifer M Walton MD

The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our copyright policy.